Antidepressant activity

Antidepressant activity refers to the pharmacological property of a substance to alleviate the symptoms of clinical depression and other mood disorders. It is not a specific molecular target (such as a receptor or enzyme) but rather a clinical effect or therapeutic category [1]. This activity is primarily associated with the modulation of monoaminergic neurotransmission in the central nervous system, particularly involving serotonin, norepinephrine, and dopamine pathways [2][3]. Modern neurobiological theories suggest that antidepressant activity also requires downstream modifications in neuroplasticity, including the upregulation of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and the promotion of neurogenesis in the hippocampus [5]. Drugs that exhibit this activity, such as SSRIs, SNRIs, and atypical agents like ketamine, interact with diverse primary targets to achieve the ultimate clinical outcome of mood stabilization [1][6]. Because this term describes a broad physiological response rather than a discrete biological entity, it is considered an incorrect entry for a specific drug target database.

Other names

Thymoleptic activityMood-elevating effectAntidepressant effectAntidepressant action

Antidepressant activity is not a single mechanism but a therapeutic outcome achieved by increasing synaptic concentrations of monoamines (serotonin, norepinephrine, and dopamine) through the inhibition of reuptake transporters or metabolic enzymes like monoamine oxidase, or through the direct modulation of receptors such as the NMDA receptor [1][2].